Simplex Trading
CASC

Simplex Trading’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Simplex Trading’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-218
Closed – – 7437
2017
Q4 		$0 Buy
218
+217
+21,700% +$888 ﹤0.01% 7226
2017
Q3 		$0 Sell
1
-3,310
-100% -$12.7K ﹤0.01% 7176
2017
Q2 		$12K Buy
3,311
+3,280
+10,581% +$13K ﹤0.01% 3859
2017
Q1 		$0 Buy
+31
New +$130 ﹤0.01% 7239
2016
Q4 		– Sell
-2,701
Closed -$26K – 7016
2016
Q3 		$26K Buy
2,701
+1,034
+62% +$7.33K ﹤0.01% 2728
2016
Q2 		$9K Sell
1,667
-2,992
-64% -$20.3K ﹤0.01% 3753
2016
Q1 		$35K Buy
4,659
+2,581
+124% +$19.9K ﹤0.01% 2299
2015
Q4 		$27K Buy
+2,078
New +$35.8K ﹤0.01% 2457

Simplex Trading's CASC Position: Q1 2018 in Review

Simplex Trading sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 218 shares.

Simplex Trading first reported a position in CASC in Q4 2015 and held it in 8 quarters. The position peaked at $35K in Q1 2016. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Simplex Trading reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Simplex Trading sold 218 Cascadian Therapeutics, Inc. shares in Q1 2018.
  • Simplex Trading first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 8 quarters.
  • Simplex Trading's Cascadian Therapeutics, Inc. position peaked at $35K in Q1 2016.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Simplex Trading's 13F filing for Q1 2018, filed 26 Apr 2018.